Plugs for Fistula Repair

File Name: plugs_for_fistula_repair
Origination: 3/2010
Last CAP Review: 11/2019
Next CAP Review: 11/2020
Last Review: 11/2019

Description of Procedure or Service
Anal fistula plugs are biosynthetic devices used to promote healing and prevent recurrence of anal fistulas. The conical-shaped plug is anchored in the anal fistula and acts as a scaffold into which new tissue can grow to close the fistula. The plug is absorbed into the body in 6 to 8 weeks. The procedure may require 12–24 hours observation postoperatively. The procedure can be repeated in case of failure.

The SIS Fistula Plug from Cook Biotech received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in March 2005 based on similarity to predicate devices, including the SURGISIS® Soft Tissue Graft and the STRATASIS® Urethral Sling, both manufactured by Cook Biotech Incorporated. The SIS Fistula Plug is manufactured from porcine small intestinal submucosa (SIS) and is intended for repair of anal, rectal, and enterocutaneous fistulas. The Surgisis RVP Recto-Vaginal Fistula Plug (Cook Biotech), also manufactured from porcine small intestinal submucosa, is supplied in a tapered configuration with a button to provide increased retention of the plug and improved blockage of the fistula. It received 510(k) clearance in October 2006. In March 2009, W.L. Gore & Associates received 510(k) clearance for the BIO-A® Fistula Plug intended for use in anorectal fistulas. The GORE BIO-A Fistula Plug device comprises a porous structure of synthetic bioabsorbable PGA/TMC copolymer fiber, degraded via a combination of hydrolytic and enzymatic pathways, using the same material, technology, and three-dimensional disk with tubes mesh design as the predicate GORE Bioabsorbable Mesh hernia plug device. The indications for use and performance of the GORE BIO-A™ Fistula Plug are substantially equivalent to the predicate Cook SIS Fistula Plug. The Biodesign Anal Fistula Plug (Cook Biotech) received 510(k) clearance from FDA in May 2016. It is manufactured from porcine small intestinal submucosa, and is intended to reinforce soft tissue where a rolled configuration is required, for repair of anal, rectal, and enterocutaneous fistulas.

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy
Biosynthetic fistula plugs are considered investigational for all indications. BCBSNC does not provide coverage for investigational services or procedures.

Benefits Application
This medical policy relates only to the services or supplies described herein. Please refer to the Member’s Benefit Booklet for availability of benefits. Member’s benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.
Plugs for Fistula Repair

When Plugs for Fistula Repair are covered

Not Applicable

When Plugs for Fistula Repair are not covered

Biosynthetic fistula plugs, including plugs made of porcine small intestine submucosa or of synthetic material are considered investigational for all indications including, but not limited to, repair of anal fistulas.

Policy Guidelines

For individuals who have anal fistula(s) who receive placement of anal fistula plug(s), the evidence includes three randomized comparative trials (RCTs), a number of comparative and noncomparative nonrandomized studies, and systematic reviews of these studies. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, and treatment-related morbidity. Two RCTs comparing anal fistula plug with surgical flap treatment reported disparate findings: one reported significantly higher rates of fistula reoccurrence with anal fistula plug; the other found similar rates of reoccurrence between anal fistula plug and surgical treatment. Another RCT, which compared AFP to seton drain removal alone for patients with fistulizing Crohn disease, found no significant difference in healing rates at 12 weeks between groups. Systematic reviews of anal fistula plug repair of anal fistulas demonstrate a wide range of success rates and heterogeneity in study results. Nonrandomized studies have also reported conflicting results. The evidence is insufficient to determine the effects of the technology on health outcomes.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable codes: 46707

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources


Senior Medical Director Review 03/2010
Plugs for Fistula Repair


Policy Implementation/Update Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/13/10</td>
<td>New policy developed. Plugs for Fistula Repair are considered investigational.</td>
</tr>
<tr>
<td>6/22/10</td>
<td>Policy Number(s) removed (amw)</td>
</tr>
<tr>
<td>12/20/11</td>
<td>Removed code 0170T from Billing/Coding section. Specialty Matched Consultant Advisory Panel review 11/30/11. (adn)</td>
</tr>
<tr>
<td>1/1/13</td>
<td>Reference added. Specialty Matched Consultant Advisory Panel review 12/4/12. No change to policy statement. (sk)</td>
</tr>
<tr>
<td>1/14/14</td>
<td>Reference added. Specialty Matched Consultant Advisory Panel review 11/20/2013. No change to Policy statement. (sk)</td>
</tr>
</tbody>
</table>
Plugs for Fistula Repair

12/30/15 Reference added. Specialty Matched Consultant Advisory Panel review 11/18/2015. The word “rectal” removed from the policy statement. (sk)


1/26/18 Reference added. (sk)


12/10/19 Specialty Matched Consultant Advisory Panel review 11/20/2019. (sk)

3/10/20 Reference added. (sk)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.